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Abstract
Background:  Autoimmune  hepatitis  (AIH)  is  a  chronic  inﬂammatory  disease  of  the  liver  with
nonspeciﬁc  clinical  manifestations  that  causes  greater  liver  damage  in  children  than  in  adults.
Aims: To  analyze  the  clinical  progression,  biochemical  proﬁles,  histopathologic  changes,  and
treatment  response  in  20  children  with  AIH.
Material  and  methods:  A  retrospective  study  was  carried  out  on  the  variables  associated  with
clinical progression,  diagnosis,  and  treatment  response  in  children  seen  at  the  the  Unidad
Médica de  Alta  Especialidad  (UMAE)  No.  71  IMSS  in  Torreón,  Coahuila,  Mexico,  from  1992  to
2012.
Results:  Twenty  patients  were  analyzed,  75%  with  type  1  AIH  (AIH-1)  and  25%  with  type  2  AIH
(AIH-2). Girls  predominated  with  a  3:1  ratio  of  girls  to  boys.  The  mean  age  was  10.07  ±  6.53
years for  the  AIH-1  cases  and  6.75  ±  3.77  years  for  the  AIH-2  cases.  There  was  an  association
with immunologic  diseases  in  40%  of  the  patients.
The patients  in  the  AIH-2  group  had  greater  biochemical  proﬁle  alterations  and  IgA  deﬁciency.
Anti-nuclear  antibody  and  anti-smooth  muscle  antibody  were  positive  in  100%  of  the  patients
with AIH-1,  and  anti-liver  kidney  microsomal  type  1  antibody  was  positive  in  100%  of  the  AIH-2
patients. Liver  biopsy  revealed  interface  hepatitis  in  both  groups.  The  AIH-2  group  responded
more quickly  to  treatment,  but  had  a  higher  recurrence  rate. Please cite this article as: Nares-Cisneros J, Jaramillo-Rodríguez Y. Hepatitis autoinmune en nin˜os: evolución de 20 casos del norte de
éxico. Revista de Gastroenterología de México. 2014;79:238--243.
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Conclusions:  Autoimmune  hepatitis  in  the  pediatric  patient  should  be  suspected  in  order  to
make an  early  diagnosis  and  thereby  establish  opportune  treatment.  Determining  the  type  of
AIH is  necessary  for  making  adequate  diagnosis  and  for  achieving  a  better  outcome  in  relation
to recurrence  and  complication  rates.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Hepatitis  autoinmune  en  nin˜os:  evolución  de  20  casos  del  norte  de  México
Resumen
Antecedentes:  La  hepatitis  autoinmune  (HAI)  es  una  enfermedad  inﬂamatoria  crónica  del
hígado con  manifestaciones  clínicas  inespecíﬁcas  y  mayor  dan˜o hepático  en  nin˜os  que  en  adultos.
Objetivo:  Analizar  la  evolución  clínica,  los  perﬁles  bioquímicos,  los  cambios  histopatológicos  y
la respuesta  al  tratamiento  de  20  nin˜os  con  HAI.
Material  y  métodos: Estudio  retrospectivo  de  las  variables  asociadas  a  evolución  clínica,  diag-
nóstico y  respuesta  al  tratamiento  en  nin˜os  atendidos  en  la  UMAE  n.◦ 71  IMSS  Torreón,  Coahuila,
México,  en  el  período  comprendido  entre  1992  y  2012.
Resultados:  Se  analizó  a  20  pacientes,  el  75%  con  HAI-1  y  el  25%  con  HA1-2.  Se  observó  pre-
dominio del  sexo  femenino  3:1.  La  edad  promedio  ±  desviación  estándar  fue  de  10.07  ±  6.53
an˜os para  HAI-1  y  de  6.75  ±  3.77  para  HAI-2.  La  asociación  a  enfermedades  inmunológicas  fue
del 40%.
Los  pacientes  del  grupo  HAI-2  mostraron  mayores  alteraciones  en  su  perﬁl  bioquímico  y  deﬁ-
ciencia de  IgA.  La  positividad  para  anticuerpos  antinucleares  y  anticuerpos  antimúsculo  liso  fue
del 100%  en  los  pacientes  con  HAI-1,  anticuerpos  antimicrosomales  para  hígado  y  rin˜ón  tipo  1
en el  100%  de  HAI-2.  Las  biopsias  hepáticas  mostraron  hepatitis  de  interfase  en  ambos  grupos.
Los pacientes  del  grupo  HAI-2  respondieron  más  rápidamente  al  tratamiento  y  tuvieron  mayor
tasa de  recaídas.
Conclusiones:  Es  necesario  sospechar  la  HAI  en  pediatría  para  poder  realizar  un  diagnóstico
temprano  y  así  establecer  el  tratamiento  oportuno.  Determinar  el  tipo  de  HAI  nos  permitirá
establecer  el  diagnóstico  adecuado  y  elaborar  un  mejor  pronóstico  respecto  a  tasas  de  recaídas
y complicaciones.
©  2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Autoimmune  hepatitis  (AIH)  is  a  chronic  inﬂammatory
process  involving  cell  destruction  and  ﬁbrosis.  It  pre-
dominantly  affects  women  and  is  characterized  by  an
increase  in  transaminases  and  immunoglobulins,  in  partic-
ular  immunoglobulin  G  (IgG).
AIH  has  2  main  variants:  type  1  (AIH-1)  and  type  2  (AIH-
2).  AIH-1  is  the  most  common  form,  affecting  children  and
adults,  and  is  characterized  by  the  presence  of  anti-nuclear
antibody  (ANA)  and  anti-smooth  muscle  antibody  (SMA).
AIH-2  mainly  affects  children  and  young  adults  and  is  char-
acterized  by  the  presence  of  anti-liver/kidney  microsomal
type  1  antibody  (LKM-1).  The  diagnostic  criteria  for  AIH  were
published  by  the  International  Autoimmune  Hepatitis  Group
in  1993,1 in  1999,2 and  simpliﬁed  in  2008.3,4These  criteria  include:  the  exclusion  of  infectious  viral
processes,  antibody  proﬁles  (ANA,  SMA,  LKM-1),  IgG  levels
1.10-fold  above  the  normal  limits,  and  a  histologic  pattern  of
interface  hepatitis  with  plasma  cells  and  rosette  formation.
w
e
c
(cute  AIH  presents  in  children  and  young  adults  and  is  more
ggressive  than  in  older  adults.5,6
ims
he  aim  of  this  study  was  to  analyze  the  clinical  progression,
iochemical  proﬁles,  histopathologic  changes,  and  treat-
ent  response  in  20  children  presenting  with  AIH.
ethods
wenty  children  diagnosed  with  AIH  that  were  seen  at  the
utpatient  service  of  the  Department  of  Gastroenterology
nd  Pediatric  Nutrition  of  the  Advanced  Speciality  Medi-
al  Unit  No.  71  of  the  Instituto  Mexicano  del  Seguro  Social
ithin  the  time  frame  of  1992  and  2012  were  studied.  In
ach  case,  the  disease  was  classiﬁed  in  accordance  with  the
riteria  of  the  International  Autoimmune  Hepatitis  Group
IAIHG)  and  reclassiﬁed  with  the  2008  simpliﬁed  diagnostic
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Table  1  Clinical  ﬁndings  in  the  presentation  of  AIH-1  and  AIH-2.
AIH-1  (n  =  15)  AIH-2  (n  =  5)  p  value
Age  in  years  (mean  ±  SD)  10.07  ±  6.53  6.75  ±  3.77  0.001*
Female  (%)  73.33  80  0.095
Presentation  mode
Acute  hepatitis  (%)  53.33  40  0.05*
Acute  liver  failure  (%)  6.67  20  0.03*
Insidious  onset  (%)  20  20  0.649
Complication  of  chronic  liver  disease  (%)  13.3  20  0.05*
Association  with  immunologic  diseases  (%)  20  40  0.043*
Inﬂammatory  bowel  disease  (%) 6.67 20  0.001*
Family  history  of  autoimmune  diseases  (%) 13.3 40  0.001*
Abnormal  cholangiogram  (%) 0  0  0.755
Chi-square test, Fisher exact test.
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i* statistical signiﬁcance with a p ≤ 0.05.
riteria,  and  the  data  of  the  following  variables  were  col-
ected:  age,  sex,  type  of  clinical  presentation,  association
ith  immunologic  diseases,  clinical  manifestations,  liver
unction  tests,  serum  albumin,  INR,  serum  immunoglobulins,
iver  biopsy  ﬁndings,  progression  time,  treatment,  recurren-
es,  and  complication  frequency.
Statistical  analysis:  the  results  were  analyzed  using  the
tudent’s  t  test  and  the  Wilcoxon  test  for  determining  the
ean  differences.  Statistical  signiﬁcance  was  set  at  a  value
f  p  ≤  0.05  (SPSS  version  17.0  statistical  software,  Chicago,
L,  USA).
esultsf  the  20  patients  analyzed,  15  (75%)  presented  with  AIH-1
nd  5  presented  with  AIH-2.  The  population  was  made  up
f  15  girls  and  5  boys,  with  a  3:1  proportion.  The  mean  age
as  10.07  ±  6.53  in  the  patients  with  AIH-1  and  6.75  ±  3.77
(
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Table  2  Immunologic  and  biochemical  ﬁndings  in  the  presentatio
Laboratory  ﬁndings  AIH-1  (n  =  15)  
Total  bilirubin  (mg/dl)  2.5  (1.6-23)  
AST  (IU/l)  650  (85-1,700)  
ALT(IU/l)  530  (90-1,400)  
GGT  (IU/l)  115  (15-788)  
ALP (IU/l)  340  (130-1,500)  
Total proteins  (g/dl)  8.5  (7-8.9)  
Albumin (mg/dl)  2.9  (2.3-3)  
INR  1.1  (1.4-1.7)  
IgG  (mg/dl)  2,350  (1,300-3,200)  
IgA (mg/dl)  135  (54-226)  
IgM  (mg/dl)  196  (145-750)  
Serum C4  (md/dl)  14  (93%)  
ANA+ SMA+  (%)  15  (100%)  
SLA  +  (%)  6  (40%)  
LKM-1  +  (%)  0  
pANNA  +  (%)  7  (46%)  
Chi-square test, Fisher exact test.
* statistical signiﬁcance with a p ≤ 0.05.n  the  patients  with  AIH-2.  The  main  presentation  mode  was
cute  hepatitis  in  the  two  groups,  although  the  frequency
as  slightly  higher  in  the  AIH-1  group.  There  was  a  greater
requency  of  other  immunologic  diseases  in  the  AIH-2  group,
uch  as  thyroiditis  and  ulcerative  colitis  (UC)  (Table  1).
The  biochemical  proﬁle  included  the  determination  of
otal  bilirubin  (TB),  direct  bilirubin  (DB),  indirect  bilirubin
IB),  aminotransferases  (AST,  ALT,  GGT),  alkaline  phos-
hatase  (ALP),  total  proteins,  albumin  and  globulin,  the
rothrombin  time  (PT)  and  international  normalized  ratio
INR)  coagulation  tests.  The  immunologic  proﬁle  was  car-
ied  out  and  IgG,  IgM,  IgA,  complement  component  4  (C4),
nti-nuclear  antibodies  (ANA),  anti-smooth  muscle  antibod-
es  (SMA),  anti-liver/kidney  microsomal  type  1  antibodies
LKM-1)  were  also  determined.
All  the  cases  of  AIH-1  were  positive  for  ANA  and/or
MA,  and  all  the  AIH-2  patients  were  positive  for  LKM-1.
ther  antibodies  such  as  the  anti-soluble  liver  antigen  (SLA)
n  of  AIH-1  and  AIH-2.
AIH-2  (n  =  5)  p  value
9.5  (3.6-37)  0.009*
1100  (95-2,300)  0.046*
980  (100-2,100)  0.040*
85  (38-250)  0.59
345  (95-1,760)  0.095
8.3  (6.8-8.7)  0.30
3.6  (2.7-5.1)  0.03*
1.5  (1.8-2.6)  0.042*
2180  (1,100-2,700)  0.07
45  (28-55)  0.005*
203  (137-823)  0.67
4  (80%)  0.06
0  (0%)  0.001*
3  (60%)  0.03*
5  (100%)  0.001*
1  (25%)
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Table  3  Histopathologic  ﬁndings  in  the  presentation  of
AIH-1 and  AIH-2.
Histopathologic  ﬁndings  AIH-1  (n  =  15)  AIH-2  (n  =  5)
Interface  hepatitis  (%)  100  100
Plasma  cells  (%)  100  100
Rosettes  (%)  46.6  40
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Cirrhosis  (%)  60  40
antibody  were  positive  in  both  groups,  and  predominated  in
the  AIH-2  patients  at  60%  (Table  2).
A  liver  biopsy  was  taken  and  interface  hepatitis  with
plasma  cells  was  observed  in  all  the  cases.  Rosette  forma-
tion  and  cirrhosis  were  more  frequent  in  the  AIH-1  group.
No  changes  in  the  biliary  ducts  were  observed  in  any  of  the
cases  (Table  3).
The  patients  in  the  AIH-2  group  responded  to  treat-
ment  more  quickly,  but  the  recurrence  rate  was  higher.  The
patients  in  the  AIH-1  group  had  a  higher  remission  rate  and
for  a  longer  period  of  time  than  the  AIH-2  patients  (Table  4).
The  initial  established  treatment  was  prednisone  (PDN)
at  a  dose  of  2  mg/kg/day,  with  a  maximum  dose  of  60  mg
per  day.  This  treatment  lasted  a  mean  of  8  weeks  and  was
given  until  achieving  a  decrease  of  at  least  80%  in  the  serum
levels  of  AST  and  ALT  from  their  initial  values.
The  steroids  were  then  progressively  reduced  until  the
aminotransferases  were  normalized.  When  this  goal  was
achieved,  a  maintenance  dose  of  PDN  of  5  mg  daily  was
established.  If  the  goal  was  not  reached,  azathioprine  (AZA)
at  0.5-2.5  mg/kg/day  was  given  until  AST  was  normalized.
A  maintenance  dose  of  AZA  at  0.5  mg/kg/day  was  contin-
ued.  If  there  was  response  failure  or  signs  of  toxicity,
Table  4  Treatment  response  and  progression  in  the  pre-
sentation  of  AIH-1  and  AIH-2.
Progression AIH-1  (n  =  15) AIH-2  (n  =  5)
Time  necessary  for
AST  normalization
(months)
3  1
Normalization  after
beginning
treatment  (%)
85  75
Initial  remission  rate
(%)
93.3  80
Mean  remission
duration  (months)
7  4
Recurrence  rate  (%)  45  60
Successful  treatment
suspension  (%)
20  0
Liver  transplantation
rate  (%)
6.67  20
Post-transplantation
disease  recurrence
0  0
Median
transplantation-
free survival
(months)
12  5
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ycophenolate  mofetil  at  20  mg/kg  was  started.
yclosporine  or  tacrolimus  was  used  when  there  was
 lack  of  response  or  when  there  was  toxicity,  which
ccurred  in  6.67%  (n  =  1)  of  the  AIH-1  cases  and  in  20%
n  =  1)  of  the  AIH-2  cases.  These  2  patients  underwent  liver
ransplantation.
iscussion
he  deﬁnitive  diagnosis  for  AIH  is  made  based  on  clini-
al,  laboratory,  and  histopathologic  criteria  that  have  been
eﬁned  by  the  IAIHG.
Some  of  these  criteria  are  directly  related  to  the  diag-
osis  and  some,  such  as  partial  IgA  deﬁciency  observed  in
IH-2  patients,  have  been  associated  with  worse  outcome.7
Even  though  autoantibodies  are  an  essential  part  of  the
IH  diagnosis,  ANA,  SMA,  and  LKM-1  are  not  detected  at  the
ime  of  clinical  presentation  in  10  to  15%  of  the  patients,
ut  they  become  detectable  later;  they  remain  negative  in
nly  5%  of  the  patients.8--10 In  these  cases  the  presence  of  the
ther  criteria,  such  as  an  increased  IgG  level  and  histopatho-
ogic  changes  observed  in  the  liver  biopsies,11 are  diagnostic
eterminants.
In the  diagnostic  criteria,  titers  of  1:40  for  ANA,  SMA,
nd  LKM-1  have  been  established  as  positive;  this  is  appli-
able  to  adults,  but  for  children  a  titer  of  1:20  for  ANA  and
MA  and  of  1:10  for  LKM-1  are  sufﬁcient.12 We  found  SLA
ositivity  in  both  AIH  groups,  with  a  predominance  in  the
IH-2  group.  This  is  related  to  a  more  severe  disease  course
nd  a  greater  recurrence  tendency,13 as  was  seen  in  the
IH-2  patients  and  in  the  two  patients  that  required  liver
ransplantation.  In  order  to  make  the  deﬁnitive  diagnosis,
 liver  biopsy  is  required,  along  with  taking  into  account
he  abovementioned  histopathologic  criteria  with  a  high
peciﬁcity  of  81-99%,  but  a  low  sensitivity  of  36-57%,  and
 positive  predictive  value  (PPV)  of  62-91%.14 In a  blinded
tudy  for  pathologists,  Kumari  N  et  al.15 compared  liver  biop-
ies  of  autoimmune  and  non-autoimmune  liver  disease.  They
ound:  interface  hepatitis,  lymphoplasmacytic  portal  inﬁl-
rate,  emperipolesis,  and  rosette  formation  in  56%  of  the
ases  of  autoimmune  liver  disease.  When  3  out  of  4  changes
ere  considered,  the  diagnostic  accuracy  for  AIH  was  76.9%,
ith  a  PPV  of  93.3%  and  a  negative  predictive  value  (NPV)  of
0.7%.  Cirrhosis  of  the  liver  was  present  in  a  high  proportion
f  cases,  and  predominated  in  the  AIH-1  group  (60%).  Fortes
t  al.16 reported  that  patients  that  had  the  HLADRB1-1301
llele  had  a  higher  risk  for  presenting  with  cirrhosis.  Cir-
hosis  presents  in  44  to  80%  of  the  cases  in  children  at  the
ime  of  diagnosis  and  they  remain  clinically  stable  with  a
ow  mortality  rate  and  good  quality  of  life  with  long-term
reatment.17
Treatment  goals  are  to  improve  symptoms,  induce  bio-
hemical  remission,  subdue  hepatic  inﬂammation,  and
rolong  survival.18 Clinical  and  biochemical  remission  do
ot  necessarily  reﬂect  histologic  resolution,  given  that  the
istopathologic  changes  take  longer.19 It  is  stated  that  after
 years  of  treatment,  improvement  in  ﬁbrosis  and  the  inten-
ity  of  portal  inﬂammation  is  observed  in  more  than  95%  of
he  cases.
Adequate  treatment  response  was  faster  in  the  AIH-2
roup  and  on  average  it  was  seen  within  the  ﬁrst  month  of
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reatment.  However,  there  was  a  poor  response  in  20%  of  the
ases  in  that  group.  Outcome  and  treatment  response  in  chil-
ren  have  been  associated  with  the  genetic  and  immunologic
arkers  such  as  HLA-DRB1*1301  and  DRB1*07.20--23 In  a  study
y  Czaja  et  al.,24 they  concluded  that  the  patients  with  HLA-
RB1*03  were  younger  at  the  time  of  disease  onset  and  had  a
orse  response  to  steroid  treatment  than  the  patients  with
LA-DRB1*04;  these  latter  patients  were  more  frequently
omen  that  had  an  association  with  other  immunologic
iseases.25 The  class  II  histocompatibility  antigen  (MHC  II)
LA-DRB1*04  antigen  was  more  common  in  ethnic  groups  in
exico  and  Japan.26
Relapses  are  common  during  the  course  of  treatment.
n  our  study,  45%  of  the  cases  with  AIH-1  and  60%  of  the
ases  with  AIH-2  had  disease  recurrences,  causing  a  tempo-
ary  increase  in  steroid  dose.  In  a  study  by  Van  Gerven  et  al.27
onducted  on  a  cohort  of  131  patients,  they  reported  a  47%
ecurrence  rate.  The  greatest  relapse  risk  was  observed  in
ery  young  patients  that  also  presented  with  a  concomitant
utoimmune  disease.
Another  factor  associated  with  disease  recurrence  is  the
ack  of  treatment  adherence.  In  our  population,  20%  of  the
ases  in  each  group  did  not  adhere  to  treatment,  a  ﬁgure
imilar  to  that  reported  by  Sotelo  y  López28 in  2005  in  a
tudy  on  Mexican  children  from  Hermosillo,  Sonora,  in  which
reatment  abandonment  was  22%.29
Successful  treatment  suspension  was  achieved  in  only
0%  of  the  patients  with  AIH-1  and  in  none  of  the  patients
n  the  AIH-2  group.  Therefore,  treatment  suspension  is
ot  recommended  for  AIH-2  patients  because  relapses  are
ore  frequent  and  remission  failure  is  an  almost  cer-
ain  condition.30 In  a  population-based  retrospective  cohort
tudy,  Deneau  et  al.31 found  a  sustained  immunosuppressant
herapy-free  remission  in  41.6%  of  the  pediatric  patients
ithin  the  ﬁrst  5  years  of  diagnosis.
With  respect  to  the  type  of  treatment,  it  is  important  to
nderline  the  favorable  response  to  steroids  and  immuno-
uppressant  drugs  in  AIH.32--34 Response  is  achieved  through
he  exclusive  use  of  PDN  or  in  combination  with  AZA.  Another
ption  is  budenoside,  which  has  fewer  side  effects  and  more
apid  hepatic  elimination.  However,  it  cannot  be  used  in
atients  with  cirrhosis,  a  complication  that  limits  its  use
n  a  large  proportion  of  patients  with  AIH.  In  a  cohort  of
ediatric  patients,  Mieli-Vergani  et  al.35 compared  the  use
f  budenoside  with  AZA  versus  PDN  with  AZA  and  found  no
ifference  in  the  remission  rate  at  6  and  12  months.  When
here  is  treatment  failure,  the  medications  employed  are
yclosporine,  tacrolimus,  and  mycophenolate  mofetil.
Standard  therapy  with  PDN-AZA  is  effective  in  85%  of
he  cases,36 but  there  are  other  alternatives  that  should
e  considered.  The  infusion  of  antigen-speciﬁc  regulatory
 cells  for  restituting  the  damaged  immunologic  regulation
nd  restoring  the  lost  peripheral  tolerance37--42 has  been  sug-
ested  for  AIH-2  management,  but  its  availability  is  limited.
Optimum  duration  of  immunosuppressant  treatment  is
ontroversial  and  it  is  only  considered  successful  if  inﬂam-
ation  is  histologically  resolved  after  one  or  two  years
f  treatment  in  which  there  are  normal  transaminase  and
mmunoglobulin  levels,  as  well  as  autoantibody  negativ-
ty.  Note:  in  order  for  optimum  treatment  duration  to  be
onsidered,  there  must  be  remission;  this  is  deﬁned  as
he  absence  of  symptoms  and  the  normalization  of  serumJ.  Nares-Cisneros,  Y.  Jaramillo-Rodríguez
mmunoglobulins,  ALT/AST  aminotransferases,  and  autoan-
ibodies.  It  must  also  be  demonstrated  histopathologically,
ith  minimum  inﬂammation  and  no  necrosis.  It  is  suggested
ot  to  suspend  treatment  within  the  ﬁrst  3  years  of  the  diag-
osed  disease,  or  immediately  before  puberty,  due  to  the
ossibility  of  frequent  relapses.
Unlike  the  patients  with  autoimmune  sclerosing  cholan-
itis,  AIH  patients  have  better  treatment  response,  with  a
etter  survival  rate,  and  they  require  a low  dose  of  mainte-
ance  medication.43
Ngu  et  al.44 analyzed  the  poor  treatment  response  predic-
ors  that  included  incomplete  ALT  normalization  at  6  months
f  management,  low  albumin  concentration,  and  age  ≤  20
ears  and  ≥  60  years.  These  variables  were  independent
redictors  for  the  necessity  of  liver  transplantation  and/or
he  possibility  of  death.  However,  cirrhosis  was  not  asso-
iated  with  poor  outcome  and  did  not  inﬂuence  the  initial
mmunosuppressant  treatment  response.
onclusions
utoimmune  hepatitis  must  be  suspected  in  pediatric
atients  in  order  to  make  early  diagnosis  and  thus  establish
pportune  treatment.  Diagnostic  delay  results  in  cirrhosis
nd  liver  failure.
AIH  in  children  presents  in  acute  form  and  has  a  more
ggressive  disease  course  than  in  adults.
The  presence  of  cirrhosis  does  not  modify  treatment
esponse.
Optimum  treatment  response  is  achieved  more  rapidly
n  patients  with  AIH-2,  but  they  also  present  with  higher
ecurrence  rates  within  a  shorter  period  of  time.
The  presence  of  SLA  autoantibodies  is  associated  with
n  inferior  treatment  response  and  higher  recurrence  fre-
uency.
Relapses  are  common  in  the  course  of  treatment,  pre-
enting  in  45-60%  of  the  cases  and  they  are  observed  more
requently  in  patients  with  AIH-2.
The  combination  of  PDN  +  AZA  is  the  initial  treatment  of
hoice.
Further  genetic  studies  and  analyses  of  immunologic
arkers  are  required  that  will  aid  in  determining  the  suscep-
ibility  of  presenting  with  AIH  and  in  establishing  outcome
nd  treatment  response  factors.
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